US/UK/Canada

Share

Links

Pick a time period -
Tags ( Active)

Oncoinvent achieves 50% recruitment milestone in Phase 2 ovarian cancer study of Radspherin[®]

· Strong recruitment momentum demonstrated in 2026 · Year-to-date recruitment has already surpassed total enrollment for 2025Oslo, Norway, 18 June 2026: Oncoinvent, a clinical-stage radiopharmaceutical company developing Radspherin[®], a receptor-independent alpha-emitting therapy to eradicate cancer cells in the abdominal cavity after surgery with a single, targeted dose, today announces that its ongoing Phase 2 trial of Radspherin[®] in patients with peritoneal metastases from ovarian cancer has reached the 50% patient recruitment milestone. A total of 54 patients have now been

Oncoinvent ASA: Grant of share options to member of the Board following AGM

Oslo, Norway, 20 May 2026: Reference is made to the Annual General Meeting (the “AGM”) of Oncoinvent ASA (the “Company”) earlier today where the nomination committee's proposal for remuneration for the members of the Board was approved. The AGM approved the following share option remuneration to the Board. · Chair of the Board: 1,708 share options · Board members: 854 share options Share options normally vest over a four-year period as follows: no options shall vest during the first 12 months following the date of the grant, 13/48 of the options shall vest in the 13th month,

Oncoinvent ASA: Minutes from Annual General Meeting

20 May 2026, Oslo Norway: The Annual general meeting of the Company was held today, 20 May 2026, by electronic means through Lumi AGM. All proposals on the agenda were adopted in accordance with the proposals set out in the notice dated 28 April 2026. The complete minutes of the ordinary general meeting are attached to this release and are also available on the Company's website, https://www.oncoinvent.com/investors/general-meetings/.  Oncoinvent ASA - Minutes of Annual General Meeting 20 May 2026 

Oncoinvent ASA: Share capital decrease completed

Oslo, Norway, 5 May 2026: Reference is made to the stock exchange announcement made by Oncoinvent ASA (the "Company") on 8 January 2026 regarding the resolution by the extraordinary general meeting to decrease the share capital of the Company by NOK 222,800,997, from NOK 223,920,600 to NOK 1,119,603, through a reduction of the nominal value of the shares by NOK 49.75, from NOK 50 to NOK 0.25. The resolution was published by the Norwegian Register of Business Enterprises on 22 January 2026 and followed by a six-week creditor notice period, which was completed without creditor objections.

Oncoinvent presents corporate update in live webcast

Oslo, Norway, 29 April 2026 - Oncoinvent ASA (ONCIN), a biotech company developing a receptor-independent alpha radiopharmaceutical to eradicate cancer cells in the abdominal cavity after surgery with a single, targeted dose, is hosting a live webcast at 8:00 AM CET today, Wednesday, 29 April 2026. · Presenters: CEO Øystein Soug, CFO Ramzi Amri · Time: 8:00am CET · Webcast link: https://qcnl.tv/p/ZTQdC_4834AF6CKrux8XCw   Highlights: · Recruited and randomized 37 patients (accumulated, ITT*) into the ovarian Phase 2 trial · Secured new patent expanding protection for

Oncoinvent ASA: Notice of Annual General Meeting

Oslo, Norway, 28 April 2026 - Oncoinvent ASA (ONCIN), will be holding its Annual General Meeting virtual on 20 May 2026 at 10:00 hours (CEST). The notice and agenda of the annual general meeting is attached hereto, including further information on advance voting, power of attorney and physical participation. The notice will be sent to all registered shareholders, and the notice, the compensation report, the nomination committees recommendations and other documents referred to therein are made available on the Company's website: https://www.oncoinvent.com/investors/general-meetings/.

Oncoinvent ASA: Invitation to business update Wednesday 29 April 2026

Oslo, Norway, 23 April 2026 - Oncoinvent ASA (ONCIN), a biotech company developing a receptor-independent alpha radiopharmaceutical to eradicate cancer cells in the abdominal cavity after surgery with a single, targeted dose, is pleased to invite investors, analysts, and stakeholders to a live webcast event at 8:00 AM CET on Wednesday, 29 April 2026. Webcast:  · Date: Wednesday, 29 April 2026 · Time: 8:00am CET · Webcast link: click here for link   The presentation will on the same day be made available on the Investor Relations

Oncoinvent ASA: Annual Report for 2025

Oslo, Norway, 22 April 2026 - Oncoinvent ASA (ONCIN), a biotech company developing a receptor-independent alpha radiopharmaceutical to eradicate cancer cells in the abdominal cavity after surgery with a single, targeted dose, today announced the publication of the Annual Report for 2025. The Board of Oncoinvent ASA has approved the annual accounts for 2025. The financial statements and annual report for the financial year 2025 are attached in European Single Electronic Format (ESEF) and as a PDF file. The documents are also available in the investors section of the Company’s website:

Oncoinvent secures new patent expanding protection for Radspherin[®]

First patent from a new patent family granted in China, strengthening the long‑term intellectual property protection for the Company’s lead product candidate.Oslo, Norway, 19 March 2026: Oncoinvent (OSE: ONCIN), a biotech company developing a receptor-independent alpha radiopharmaceutical to eradicate cancer cells in the abdominal cavity after surgery with a single, targeted dose, today announces that the China National Intellectual Property Administration (CNIPA) has granted a new patent for Radspherin[®], the Company’s lead product candidate, marking the first approval worldwide within

Oncoinvent ASA: Grant of share options to the CEO

Oslo, Norway, 11 March 2026: The Board of Directors has today resolved to grant CEO Øystein Soug 31,884 share options in the Company under the Company's long term incentive program, each with a strike price of NOK 42.98, equal to the volume weighted average share price the last day before the grant. See the attached form. Following the grant of the 31,884 share options referred to above, Øystein Soug hold 10,576 shares and 92,949 options in the Company. Each option, when exercised, will give the right to acquire one share in the Company. The options are granted without consideration. No

Oncoinvent ASA: Second half 2025 results

Oslo, Norway, 26 February 2026: Oncoinvent (OSE: ONCIN), a biotech company developing a receptor-independent alpha radiopharmaceutical to eradicate cancer cells in the abdominal cavity after surgery with a single, targeted dose, today announces its second half 2025 results. Oncoinvent’s management team will give an online presentation to investors, analysts and the press at 09:30 CET today (details below). Highlights: Radspherin[®] · Reported positive final data from Phase 1 Trial of Radspherin[®] to treat ovarian cancer · Published Phase 1 trial results for Radspherin[®]

Oncoinvent to Present Positive 24-month Follow-up Data from Phase 1 Ovarian Cancer Study of Radspherin[®] at ESGO 2026

· 9 of 10 patients at the highest dose remained free from peritoneal recurrence at 24 months at the recommended doseOslo, Norway, 17 February 2026 – Oncoinvent (OSE: ONCIN), a biotech developing a receptor-independent alpha radiopharmaceutical to eradicate cancer cells in the abdominal cavity after surgery with a single, targeted dose, today announced that it will present final 24‑month results from its RAD-18-001 Phase 1 study of Radspherin[®] after cytoreductive surgery in patients with platinum‑sensitive epithelial ovarian cancer and peritoneal recurrence at the European Society of

Oncoinvent ASA: Announces webcast presentation of second half 2025 results on Thursday 26 February 2026

Oslo, Norway, 16 February 2026: Oncoinvent ASA (ONCIN), a biotech company developing a receptor-independent alpha radiopharmaceutical to eradicate cancer cells in the abdominal cavity after surgery with a single, targeted dose, is pleased to invite investors, analysts, and stakeholders to a live webcast event at 9:30 AM CET on Thursday, 26 February 2026.   During the webcast, Oncoinvent’s management team will present a corporate update and discuss the company’s financial results for the second half of 2025.   Second half 2025 webcast: · Date: Thursday, 26 February 2026 ·

Four additional sites open for recruitment in Oncoinvent’s Phase 2 trial

· First patient enrolled in newly activated siteOslo, Norway, 29 January 2026: Oncoinvent, a clinical stage, radiopharmaceutical company developing innovative treatments for solid cancers, today announces that the first patient has been enrolled at one of the newly activated sites in its Phase 2 study of Radspherin[®] in patients with peritoneal carcinomatosis from ovarian cancer. The randomized part of the study has been actively recruiting patients at six sites since March 2025. Four additional sites have now been opened, and the first patient has been enrolled at one of these newly

Oncoinvent ASA: Registration of reverse share split

Oslo, Norway, 20 January 2026: Reference is made to the stock exchange announcement made by Oncoinvent ASA (the "Company") on 8 January 2026 regarding the Company's extraordinary general meeting resolving a reverse share split of the Company's shares in the ratio 100:1. The reverse share split has today been registered with the Norwegian Register of Business Enterprises. Following the registration, the share capital of the Company is NOK 223,920,600 divided into 4,478,412 shares, each with a nominal value of NOK 50.

Oncoinvent ASA – New share capital registered

Oslo, Norway, 15 January 2026: Reference is made to the stock exchange announcement made by Oncoinvent ASA (the "Company") on 8 January 2026 regarding the resolution by the extraordinary general meeting of the Company to increase the share capital in connection with the issuance of 75 new shares to Abakus Invest AS for purposes of facilitating a reverse share split. The share capital increase referred to above has today been registered with the Norwegian Register of Business Enterprises (Nw.: Foretaksregisteret). The new shares will be issued and registered in the CSD with ISIN NO

Oncoinvent ASA: Key information relating to the reverse share split and change of ISIN

Oslo, Norway, 14 January 2026: Reference is made to the stock exchange announcement made by Oncoinvent ASA (the "Company") on 8 January 2026 regarding the resolution by the Company's extraordinary general meeting to carry out a reverse share split of the Company's shares. Key information related to the reverse share split, including the relevant key dates that have been determined by the board of directors today in accordance with the resolution by the general meeting, is set out below: · Date on which the corporate action was made public: 18 December 2025 · Reverse split ratio: 100:

Oncoinvent ASA: Grant of share options to new CFO

Oslo, Norway, 13 January 2026: Reference is made to the announcement made by Oncoinvent ASA ("Oncoinvent" or the "Company") 31 October 2025 regarding the appointment of Ramzi Amri as the new CEO of the Company as of January 2026. The Board of Directors has resolved to grant Ramzi Amri 5,430,000 share options in the Company under the Company's long term incentive program, each with a strike price of NOK 0.4671, equal to the volume weighted average share price the last day before the grant. Following the grant of the 5,430,000 share options referred to above, Ramzi Amri hold no shares and 5,

Oncoinvent ASA: Minutes from Extraordinary General Meeting

Oslo, Norway, 8 January 2026: An extraordinary general meeting of the Company was held today, 8 January 2026, by electronic means through Lumi AGM. The general meeting, inter alia, resolved i) audited interim balance sheet, ii) a reverse share split, iii) a capital reduction, and iv) proxy to the Board of Directors. The complete minutes of the extraordinary general meeting are attached to this release and are also available on the Company's website, https://www.oncoinvent.com/. Please see Minutes from EGM here.   

Oncoinvent ASA: Grant of share options – mandatory notification of trade

Oslo, Norway, 22 December 2025: Oncoinvent ASA (“Oncoinvent” or the “Company”) (OSE: ONCOIN), a clinical stage, radiopharmaceutical company developing innovative treatments for solid cancers, today announce that the Board of Directors has granted options to employees. As previously communicated and with the objective of aligning share option participants' interests with those of the shareholders of the Combined Company, the Board of Directors has established a replacement share option and RSU program for employees and board members similar to Oncoinvent’s program before the merger with

Oncoinvent ASA: New share capital registered

10 December 2025: Reference is made to the stock exchange announcements published by Oncoinvent ASA (the "Company") on 30 June 2025 and 4 August 2025, and subsequent announcements, regarding the contemplated fully underwritten rights issue of 260,000,000 new shares in the Company (the "Offer Shares") raising gross proceeds of NOK 130 million (the "Rights Issue"). Further, reference is made to the stock exchange announcement published by the Company on 5 December 2025 regarding the resolution by the board of directors of the Company to issue 31,199,997 new shares in the Company, each with a

Oncoinvent Announces Publication of Phase 1 Study Results for Radspherin® in Ovarian Cancer in Gynecologic Oncology

Oslo, Norway, 8 December 2025 - Oncoinvent, a clinical stage, radiopharmaceutical company developing innovative treatments for solid cancers, today announced the publication of 12-month data from its Phase 1 study of patients with platinum-sensitive recurrent ovarian cancer and peritoneal carcinomatosis. The results from the first patients have been published in the respected peer-reviewed journal Gynecologic Oncology, under the title: “First experience with intraperitoneal 224Ra-labeled microparticles after cytoreductive surgery in patients with peritoneal recurrence of platinum-sensitive

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe

Media